青春期矮小症男孩接受 GH/来曲唑治疗后的成年身高：一项基于医院病历的回顾性研究。
Adult height in pubertal boys with short stature treated with GH/letrozole: a hospital record-based retrospective study.
机构信息
Department of Pediatrics, Affiliated Hospital of Jiangnan University, Wuxi, 214122, China.
出版信息
BMC Pediatr. 2022 Jun 28;22(1):371. doi: 10.1186/s12887-022-03438-4.
BACKGROUND
The growth potential in pubertal boys with short stature is limited by the effect of estrogen on epiphyseal fusion. This study aims to identify the efficacy and safety of the combination of growth hormone (GH) and letrozole on adult height (AH) in pubertal boys with short stature.
METHODS
This is a retrospective record based study. Pubertal boys with short stature who were treated with GH and letrozole were followed up at outpatient clinics in our hospital. Twenty subjects who reached AH are reported here.
RESULTS
Baseline chronological age was 12.12 ± 1.14 yr and bone age was 13.00 ± 0.93 yr. The period of GH/letrozole treatment was 1.94 ± 0.67 yr. Height standard deviation score for bone age was increased from -1.46 ± 0.51 before treatment to -0.12 ± 0.57 after treatment (P < 0.001). The predicted AH before treatment, predicted AH after treatment, AH, and genetic target height were 161.02 ± 4.12 cm, 172.11 ± 4.20 cm, 172.67 ± 2.72 cm, and 167.67 ± 3.56 cm, respectively. There was a significant predicted AH difference before and after treatment (P < 0.001). There was a significant difference between predicted AH before treatment and genetic target height (P < 0.001). Predicted AH after therapy was higher than that of gene target height (P < 0.001), as well as AH and genetic target height (P < 0.001). There was no significant side effect.
CONCLUSIONS
GH and letrozole combination can enhance AH in pubertal boys with short stature.
背景
青春期身材矮小的男孩的生长潜力受到雌激素对骺融合的影响。本研究旨在确定生长激素（GH）和来曲唑联合治疗对青春期身材矮小男孩成年身高（AH）的疗效和安全性。
方法
这是一项基于回顾性记录的研究。在我院门诊接受 GH 和来曲唑治疗的青春期身材矮小的男孩进行了随访。报告了 20 名达到 AH 的受试者。
结果
基线时的年龄为 12.12±1.14 岁，骨龄为 13.00±0.93 岁。GH/来曲唑治疗期为 1.94±0.67 年。骨龄身高标准差评分从治疗前的-1.46±0.51 增加到治疗后的-0.12±0.57（P<0.001）。治疗前预测 AH、治疗后预测 AH、AH 和遗传靶身高分别为 161.02±4.12cm、172.11±4.20cm、172.67±2.72cm 和 167.67±3.56cm。治疗前后预测 AH 差异有统计学意义（P<0.001）。治疗前预测 AH 与遗传靶身高差异有统计学意义（P<0.001）。治疗后预测 AH 高于基因靶身高（P<0.001），也高于 AH 和遗传靶身高（P<0.001）。无明显不良反应。
结论
GH 和来曲唑联合治疗可提高青春期身材矮小男孩的 AH。
Zotero 插件